Ori-C101Chimeric Antigen Receptor (CAR) Modified T Cells for the Treatment of HCC

This study tests a CAR T-cell therapy called Ori-C101 — made from a patient's own immune cells engineered to target a protein called GPC3 — in patients with liver cancer (hepatocellular carcinoma, or HCC) that cannot be surgically removed and has not responded to other treatments. **You may be eligible if...** - You have confirmed liver cancer (HCC) with GPC3 protein expression on tumor tissue - Your cancer is at an intermediate or advanced stage and cannot be surgically removed - You have tried at least one prior systemic therapy **You may NOT be eligible if...** - Your tumor does not express GPC3 - You have severe liver dysfunction (e.g., Child-Pugh C) - You have active serious infections or significant other organ problems Talk to your doctor to see if this trial is right for you.